AGENUS INC Finance Lease, Principal Payments
AGENUS INC (AGEN) reported Finance Lease, Principal Payments of $55.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-07
- AGENUS INC finance lease, principal payments for the quarter ending 2026-06-30 was $28.00K, a 97.69% decline year-over-year.
- AGENUS INC finance lease, principal payments for the quarter ending 2026-03-31 was $27.00K, a 99.03% decline year-over-year.
- AGENUS INC finance lease, principal payments for the quarter ending 2025-12-31 was $2.99M, a 10.20% increase year-over-year.
- AGENUS INC finance lease, principal payments for the quarter ending 2025-09-30 was $678.00K, a 74.51% decline year-over-year.
- AGENUS INC finance lease, principal payments for fiscal 2025 was $7.65M, a 27.00% decline from fiscal 2024.
- AGENUS INC finance lease, principal payments for fiscal 2024 was $10.48M, a 17.42% increase from fiscal 2023.
- AGENUS INC finance lease, principal payments for fiscal 2023 was $8.93M, a 1721.63% increase from fiscal 2022.
- AGENUS INC finance lease, principal payments for fiscal 2022 was $490.00K, a 42.69% decline from fiscal 2021.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $55.00K 10-Q · filed 2026-08-07 | $3.05M derived: sum of 3 quarters · filed 2026-08-07 | $3.73M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $27.00K 10-Q · filed 2026-05-11 | $3.02M derived: sum of 2 quarters · filed 2026-05-11 | $3.70M derived: sum of 3 quarters · filed 2026-05-11 | $4.91M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.67M derived: sum of 2 quarters · filed 2026-03-16 | $4.88M derived: sum of 3 quarters · filed 2026-08-07 | $7.65M 10-K · filed 2026-03-16 |
| 2025-09-30 | $678.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.89M derived: sum of 2 quarters · filed 2026-08-07 | $4.66M 10-Q · filed 2025-11-10 | $7.37M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $3.98M 10-Q · filed 2026-08-07 | $6.70M derived: sum of 3 quarters · filed 2026-08-07 | $9.36M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $2.77M 10-Q · filed 2026-05-11 | $5.49M derived: sum of 2 quarters · filed 2026-05-11 | $8.15M derived: sum of 3 quarters · filed 2026-05-11 | $10.74M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.38M derived: sum of 2 quarters · filed 2026-03-16 | $7.97M derived: sum of 3 quarters · filed 2026-03-16 | $10.48M 10-K · filed 2026-03-16 |
| 2024-09-30 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $5.25M derived: sum of 2 quarters · filed 2025-11-10 | $7.77M 10-Q · filed 2025-11-10 | $10.39M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $5.11M 10-Q · filed 2025-08-11 | $7.73M derived: sum of 3 quarters · filed 2026-03-16 | $10.12M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | $2.51M 10-Q · filed 2025-05-12 | $5.13M derived: sum of 2 quarters · filed 2026-03-16 | $7.53M derived: sum of 3 quarters · filed 2026-03-16 | $9.55M derived: sum of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.01M derived: sum of 2 quarters · filed 2026-03-16 | $7.04M derived: sum of 3 quarters · filed 2026-03-16 | $8.93M 10-K · filed 2026-03-16 |
| 2023-09-30 | $2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.42M derived: sum of 2 quarters · filed 2024-11-12 | $6.30M 10-Q · filed 2024-11-12 | $6.55M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.91M 10-Q · filed 2024-08-08 | $4.15M derived: sum of 3 quarters · filed 2025-03-17 | $4.22M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $1.89M 10-Q · filed 2024-05-07 | $2.13M derived: sum of 2 quarters · filed 2025-03-17 | $2.20M derived: sum of 3 quarters · filed 2025-03-17 | $2.25M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $312.00K derived: sum of 2 quarters · filed 2025-03-17 | $358.00K derived: sum of 3 quarters · filed 2025-03-17 | $490.00K 10-K · filed 2025-03-17 |
| 2022-09-30 | $70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $116.00K derived: sum of 2 quarters · filed 2023-11-09 | $248.00K 10-Q · filed 2023-11-09 | $500.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $178.00K 10-Q · filed 2023-08-08 | $430.00K derived: sum of 3 quarters · filed 2024-03-14 | $646.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $132.00K 10-Q · filed 2023-05-09 | $384.00K derived: sum of 2 quarters · filed 2024-03-14 | $600.00K derived: sum of 3 quarters · filed 2024-03-14 | $796.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $468.00K derived: sum of 2 quarters · filed 2024-03-14 | $664.00K derived: sum of 3 quarters · filed 2024-03-14 | $855.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $216.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $412.00K derived: sum of 2 quarters · filed 2022-11-08 | $603.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $196.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $387.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $191.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $1.77M 10-K · filed 2023-03-16 | |||
| 2019-12-31 | $320.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |